Oaktree Capital Management Supplies $250MM in Debt Financing to Seres Therapeutics

Seres Therapeutics, a microbiome therapeutics company, entered into a new $250 million senior secured debt facility provided by funds managed by Oaktree Capital Management. Seres drew the first tranche of $110 million at closing, with three additional tranches available.

April 28, 2023 Aman Kumar | David Arkowitz | Latham & Watkins | Morgan Stanley | Oaktree Capital Management | Seres Therapeutics | Sullivan & Cromwell Ian Koplin

Oaktree Capital Management Closes New Private Debt Fund at $1.33B

Oaktree Capital Management closed Oaktree European Capital Solutions Fund III, a private debt fund that closed with a total capital commitment of €1.2 billion ($1.33 billion).

April 27, 2023 Armen Panossian | Nael Khatoun | Oaktree Capital Management Ian Koplin

Oaktree Capital Management Delivers $100MM Credit Facility to Harrow

Harrow, a U.S. eyecare pharmaceutical company, entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management.

March 29, 2023 Bryant Riley | Harrow | Mark L. Baum | Oaktree Capital Management | Steve DeNelsky Markiesha Thompson

Oaktree Capital Management Launches Oaktree Lending Partners

Oaktree Capital Management launched its private credit-focused Oaktree Lending Partners and its related vehicles (OLP). OLP is targeting $10 billion in equity commitments from institutional investors.

March 1, 2023 Armen Panossian | Howard Marks | Oaktree Capital Management Ian Koplin

Oaktree Capital Management Provides $100MM Debt Financing Agreement with scPharmaceuticals

scPharmaceuticals entered into a binding term sheet with respect to a $100 million secured debt facility with funds managed by Oaktree Capital Management.

October 11, 2022 John Tucker | Oaktree Capital Management | ScPharmaceuticals | Steve DeNelsky Ian Koplin

Oaktree Capital Management Refinances $85MM Loan Facility with Oxford Biomedica

Oxford Biomedica, a gene and cell therapy group, refinanced the $85 million secured 12-month loan facility from funds managed by Oaktree Capital Management.

October 10, 2022 Aman Kumar | Oaktree Capital Management | Oxford BioMedica | Stuart Paynter Ian Koplin

RBC Capital Markets Leads Syndicate Providing $200MM in Financing to Itafos

Itafos entered into credit facilities with a syndicate of lenders led by RBC Capital Markets, pursuant to which the lenders have advanced an $85 million term loan to the company and made available a $35 million letter of credit facility and an $80 million asset-based revolving credit facility.

September 23, 2022 CL Fertilizers Holding | G. David Delaney | Itafos | JPMorgan Chase Bank | Oaktree Capital Management | RBC Capital Markets Ian Koplin

Oaktree Capital Management Provides $225MM Credit Facility to Establishment Labs

Establishment Labs, a medical technology company focused on women’s health initially in the breast aesthetics and reconstruction market, entered into a $225 million term loan financing facility with funds managed by Oaktree Capital Management.

April 27, 2022 Aman Kumar | Cowen | Establishment Labs | Oaktree Capital Management | Raj Denhoy Ian Koplin

Oaktree Capital Management Provides $30MM in Funding to Marinus Pharmaceuticals

Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, received $30 million in funding under its existing credit agreement with Oaktree Capital Management.

April 1, 2022 Marinus Pharmaceuticals | Oaktree Capital Management Ian Koplin

Oaktree Capital Management Provides $100MM in Financing to Impel Neuropharma

Oaktree Capital Management closed two separate transactions totaling $100 million in gross funding for Impel NeuroPharma, a commercial-stage pharmaceutical company. The transactions include $50 million of senior secured debt.

March 18, 2022 Adrian Adams | Aman Kumar | Impel NeuroPharma | Oaktree Capital Management Phil Neuffer